!!!!!!!!INTERNEURON im AUFWIND!!!!! - 500 Beiträge pro Seite

[Wallgrekk]

WKN 883147, Interneuron Pharm. an der Nasdaq heute bereits über 10% im Plus. In Deutschland (Frankfurt) wird der Kurs mit großer Wahrscheinlichkeit deswegen morgen nach oben getaxt, da hier eher selten ein Handel stattfindet, bzw. das Volumen sehr gering ist.......

Der Wert ist genial. Interneuron hat sich seit anfang des Jahres mittelfristig verneunfacht(!), nach vielen Gewinnmitnahmen und dem letztwöchigen Absturz aufgrund der allgemeinen Lage, könnten wieder gute Einstiegskurse drin sein.

Ein Medikament "PRO 2000" ist bereits in Phase II/III. Es ist ein Medikament, das die Bekämpfung der Immunkrankheit AIDS verstärken soll.

Mehr infos unter www.interneuron.com

Dies ist keine Kaufempfehlung, lediglich meine persönliche Meinung!

Viel Spaß,

Wall

[Voltaires]

Four Stocks That Stand Out in Biotech`s Bargain Bin
By Adam Feuerstein
Staff Reporter
09/26/2001 07:57 AM EDT

It`s time to go hunting in the biotech bargain bin.

Related Stories
MedImmune`s Psoriasis Drug May Go More Than Skin-Deep
Sales of Amgen`s New Anemia Drug May Not Be So Sanguine
The Daily Interview: The Outlook for Biotech Stocks While the broad Amex Biotechnology Index can`t seem to put any real distance from its year lows set in April, there are some decent buys to be found if you look closely. Fair-weather biotech investors have been scared off, leaving some fundamentally sound stocks bruised but not beaten. Call them biotech bargains because fund managers are finding the low prices irresistible.

Here are four such biotech bargains, all on the buy list of various fund managers, especially at current market prices -- Praecis Pharmaceuticals (PRCS:Nasdaq - news - commentary - research), Inhale Therapeutic (INHL:Nasdaq - news - commentary - research), Bio-Technology General (BTGC:Nasdaq - news - commentary - research), Interneuron(IPIC:Nasdaq - news - commentary - research).

...
Interneuron: Talk about a company left for dead. Remember the fen-phen diet drug debacle of the late 1990s? Well, Interneuron developed the "fen" portion of the dangerous combination, which was sold through a license to American Home Products (AHP:NYSE - news - commentary - research). Both companies were buried under billions of dollars in consumer lawsuits, and Interneuron, being a small biotech, was thrown on the sector`s trash heap.

But in May, the dark cloud lifted. Interneuron was able to force AHP into a settlement that protected the company from any further legal liability. In essence, the fen-phen disaster was deemed to be an AHP problem, allowing Interneuron to focus attention on its drug development pipeline.

And one experimental drug in particular is drawing a lot of interest. The company has inked a partnership with Pfizer to develop Pagaclone as a new type of drug to treat patients suffering from panic attacks and general anxiety disorders.

Pagaclone could be a big drug because it may treat patients effectively without the bad side effects of existing drugs. Valium, for instance, is addictive and causes drowsiness, while drugs like Xanex can cause sexual dysfunction and insomnia.

Now, Pfizer is developing Pagaclone in the Big Pharma way -- that means large, time-consuming trials involving lots of patients, and not much public disclosure into how things are going. But Pfizer is expected to talk about Pagaclone`s development during its December analyst meeting, and if all goes well, the drug may reach the FDA in 2003 or 2004.

In the weeks after Interneuron inked its fen-phen settlement with AHP, the company`s stock soared to $10 a share, after trading as low as $1.15 a share. Today, Interneuron trades at about $4 a share, which makes it an attractive, low-risk investment for many institutional investors.

Übrigens, Walgreek: Nichts für ungut, aber das mit den Ausrufezeichen lass man sein. Wir sind hier doch nicht in einem Metabox oder Letsbuyit-Thread. ;-)

So long, so good!

Voltaires

[Wallgrekk]

Das ist wahr....trotzdem bedarf es bei dieser Aktie einiges an Aufsehen, eine wirklich unentdeckte Perle - besser gesagt: Eine wieder entdeckte Perle!

[mülli-2]

Aktie ist nach unten weggebrochen 200 t,Linie hat nicht gehalten,unterstützung bei 4,wenn die 4 durchbrochen wird ...dann Gummihosen anziehen

[Wallgrekk]

@mülli:

Es gab angeblich auch 2 fette Verkäufe an der Nasdaq...

Heut gab`s auch eine news, in der von div. Risiken gesprochen wird,

aber auf der Pressekonferenz werden ebenfalls die Produkte

erneut der Öffentlichkeit vorgestellt.

Anbei die News - also viel Glück am 12.10.01!!!!!


Tuesday October 9, 12:19 pm Eastern Time

Press Release

SOURCE: Interneuron Pharmaceuticals, Inc.

Interneuron to Present At
UBS Warburg Global Life
Sciences Conference

LEXINGTON, Mass.--(BUSINESS
WIRE)--Oct. 9, 2001--Interneuron
Pharmaceuticals, Inc. (NASDAQ: IPIC - news)
today announced that it will present a
corporate overview and update of its product
development programs at the UBS Warburg
Global Life Sciences Conference on Friday,
October 12, 2001 at 7:20 a.m. at the Pierre
Hotel in New York.

Interneuron`s products include: pagoclone, in
partnership with Pfizer Inc., which is
conducting Phase III clinical trials in panic
disorder and Phase II clinical trials in
generalized anxiety disorder with this
compound; trospium, in Phase III clinical trials
for overactive bladder/urinary incontinence;
dersalazine, in Phase I clinical development
for ulcerative colitis; IP 501, in Phase III
clinical trials for liver disease; and PRO 2000,
in Phase I/II clinical trials for the prevention of
the sexual transmission of HIV/AIDS.

The presentation will be audiocast live and
can be accessed by dialing 1-800-500-0177 (domestic) and
1-719-457-2679 (international). Replays will be available for up to four
weeks after the conference and can be accessed by dialing 877-710-5304
(domestic) or 402-220-0702 (international).

Interneuron Pharmaceuticals is engaged in the development and
commercialization of a portfolio of products and product candidates for
panic/anxiety disorders, overactive bladder, liver disease, prevention of HIV
infection, stroke and other disorders.

Except for the descriptions of historical facts contained herein, this press
release contains forward-looking statements that involve risks and
uncertainties that could cause the Company`s actual results and financial
condition to differ materially from those anticipated by the forward looking
statements. These risks and uncertainties are set forth in the Company`s
filings under the Securities Act of 1933 and the Securities Exchange Act of
1934 under ``Risk Factors`` and elsewhere, and include, but are not limited
to: uncertainties relating to clinical trials and regulatory approvals; need for
additional funds and corporate partners; history of operating losses and
expectation of future losses; risks relating to the Redux-related litigation;
product liability; dependence on third parties for manufacturing and
marketing; the early stage of products under development; government
regulation, patent risks and competition.

Contact:

Interneuron Pharmaceuticals, Inc.
Michael W. Rogers
Executive VP and CFO
[phone]